Product image of Meriofert Pfs (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert Pfs

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert Pfs (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to treat infertility due to anovulation and to support controlled ovarian stimulation in assisted reproductive technologies.

GNH India supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Pfs is a gonadotropin used in fertility treatment protocols that require stimulation of ovarian function.

  • Infertility due to anovulation: induces follicular development and ovulation to improve chances of conception.
  • Assisted reproductive technology cycles: provides controlled ovarian stimulation for in‑vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).
  • Ovarian stimulation for intrauterine insemination: enhances follicle growth to increase the likelihood of successful insemination.

How It Works

  • Follicle‑Stimulating Hormone (FSH) and Luteinising Hormone (LH) bind to their respective receptors on ovarian granulosa and theca cells. Activation of these receptors stimulates intracellular signaling pathways that promote follicular maturation, estradiol synthesis, and the LH surge necessary for ovulation, thereby facilitating oocyte release for fertilisation.

Side Effects

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Abdominal bloating or discomfort: transient gastrointestinal symptoms.
  • Nausea or mild headache: occasional systemic reactions.
  • Mild ovarian hyperstimulation syndrome (OHSS): mild ovarian enlargement with fluid shift.
  • Hot flashes or mild flushing: transient vasomotor symptoms.

Serious or Rare Side Effects

  • Severe OHSS: marked ovarian enlargement, ascites, thromboembolic risk.
  • Allergic reaction or anaphylaxis: rash, swelling, respiratory distress.
  • Multiple pregnancy: increased risk of twins or higher-order gestations.
  • Ectopic pregnancy: implantation outside the uterine cavity.
  • Severe abdominal pain: may indicate ovarian torsion or rupture.

Precautions & Warnings

Meriofert Pfs should be used under close medical supervision with regular monitoring of ovarian response.

  • Monitor ovarian response: adjust dosing based on ultrasound and estradiol levels.
  • Assess risk of OHSS: evaluate patient history and limit stimulation in high‑risk individuals.
  • Avoid use in uncontrolled thyroid disease: correct thyroid function before initiation.
  • Caution in patients with thromboembolic disorders: monitor for clotting complications.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert Pfs may interact with other agents that affect ovarian stimulation or coagulation.

Major Interactions (Avoid)

  • GnRH agonists: may potentiate response, increasing OHSS risk.
  • Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy.
  • Concurrent gonadotropins: additive effect can lead to excessive stimulation.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone therapy: may alter drug response, require dose adjustment.
  • Corticosteroids: can affect follicular development, monitor outcomes.
  • Anticoagulants: monitor for thrombotic events if severe OHSS occurs.

Frequently Asked Questions

Meriofert Pfs is a gonadotropin preparation containing Follicle‑Stimulating Hormone and Luteinising Hormone. It is used to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies such as IVF and ICSI.

FSH binds to receptors on ovarian granulosa cells, promoting follicle growth and estradiol production. LH binds to theca cell receptors, stimulating androgen synthesis that is converted to estrogen. Together they trigger the final maturation of the follicle and the LH surge that leads to ovulation.

The dose of Meriofert Pfs is individualized. A qualified prescriber determines the amount and schedule based on the patient’s ovarian response, treatment protocol, and monitoring results.

Meriofert Pfs is intended for use before conception to facilitate ovulation. It is not recommended for use during pregnancy, and safety during breastfeeding has not been established. Women should discuss reproductive plans with their healthcare provider.

To order Meriofert Pfs, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Meriofert Pfs combines both FSH and LH activity in a single injectable, whereas some alternatives provide only FSH. The combined formulation can simplify dosing regimens and may better mimic natural ovarian stimulation, but choice of product depends on individual protocol, physician preference and patient response.

Meriofert Pfs must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Once removed from refrigeration, use within the time frame specified by the manufacturer.

Meriofert Pfs is administered by subcutaneous injection, typically into the abdomen or thigh. The injection should be performed by a trained healthcare professional or under their supervision, following aseptic technique and the dosing schedule prescribed.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause significant abdominal distension, fluid accumulation, and thromboembolic complications, as well as allergic reactions such as anaphylaxis. Prompt medical attention is required if these symptoms occur.

Meriofert Pfs is contraindicated in patients with known hypersensitivity to its components, uncontrolled thyroid disease, active ovarian cysts, or a history of severe ovarian hyperstimulation syndrome. It should also be avoided in individuals with untreated endocrine disorders that could be exacerbated by gonadotropin therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT